Jason R Westin
Overview
Explore the profile of Jason R Westin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
7417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jallouk A, Kui N, Sun R, Westin J, Steiner R, Nair R, et al.
Haematologica
. 2023 Nov;
109(5):1460-1468.
PMID: 38031807
Complications occurring after lymphodepleting chemotherapy (LDC) may delay chimeric antigen receptor (CAR) T-cell infusion. The effect of these delays on clinical outcomes is unclear. We performed a retrospective analysis of...
12.
Gordon M, Feng L, Strati P, Lee H, Hagemeister F, Westin J, et al.
Cancer
. 2023 Nov;
130(6):876-885.
PMID: 37985359
Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non-Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often...
13.
Filosto S, Vardhanabhuti S, Canales M, Poire X, Lekakis L, de Vos S, et al.
Blood Cancer Discov
. 2023 Nov;
5(1):21-33.
PMID: 37983485
Significance: In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower...
14.
Munoz J, Flinn I, Cohen J, Sachs J, Exter B, Ranger A, et al.
Transplant Cell Ther
. 2023 Oct;
30(2):241.e1-241.e8.
PMID: 37898374
The antibody-coupled T cell receptor (ACTR) platform is an autologous engineered T cell therapy combining the cell-killing ability of T cells and the tumor-targeting ability of coadministered antibodies. Activation of...
15.
Westin J, To C, Locke F
N Engl J Med
. 2023 Sep;
389(12):1152-1153.
PMID: 37733323
No abstract available.
16.
Strati P, Li X, Deng Q, Marques-Piubelli M, Henderson J, Watson G, et al.
Cell Rep Med
. 2023 Aug;
4(8):101158.
PMID: 37586321
Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that delay recovery. While the...
17.
Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, et al.
Blood Adv
. 2023 Jun;
7(21):6785-6789.
PMID: 37389847
No abstract available.
18.
Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A, et al.
N Engl J Med
. 2023 Jun;
389(2):148-157.
PMID: 37272527
Background: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19...
19.
Westin J, Locke F, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, et al.
Clin Cancer Res
. 2023 Mar;
29(10):1894-1905.
PMID: 36999993
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of...
20.
Steiner R, Parra E, Vega F, Feng L, Westin J, Neelapu S, et al.
Exp Hematol Oncol
. 2023 Mar;
12(1):32.
PMID: 36941707
Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy,...